Jelle Wesseling
Jelle Wesseling
Verified email at - Homepage
Cited by
Cited by
Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: a collaborative analysis of data for 10,159 …
FM Blows, KE Driver, MK Schmidt, A Broeks, FE Van Leeuwen, ...
PLoS medicine 7 (5), e1000279, 2010
Reversible and adaptive resistance to BRAF (V600E) inhibition in melanoma
C Sun, L Wang, S Huang, GJJE Heynen, A Prahallad, C Robert, ...
Nature 508 (7494), 118-122, 2014
Episialin (MUC1) overexpression inhibits integrin-mediated cell adhesion to extracellular matrix components.
J Wesseling, SW Van Der Valk, HL Vos, A Sonnenberg, J Hilkens
The Journal of cell biology 129 (1), 255-265, 1995
A mechanism for inhibition of E-cadherin-mediated cell-cell adhesion by the membrane-associated mucin episialin/MUC1.
J Wesseling, SW van der Valk, J Hilkens
Molecular biology of the cell 7 (4), 565-577, 1996
Increased risk of fundic gland polyps during long‐term proton pump inhibitor therapy
M Jalving, JJ Koornstra, J Wesseling, HM Boezen, S De Jong, ...
Alimentary pharmacology & therapeutics 24 (9), 1341-1348, 2006
The association between paternal sensitivity and infant–father attachment security: A meta-analysis of three decades of research.
N Lucassen, A Tharner, MH Van IJzendoorn, MJ Bakermans-Kranenburg, ...
Journal of Family Psychology 25 (6), 986, 2011
Use of 70-gene signature to predict prognosis of patients with node-negative breast cancer: a prospective community-based feasibility study (RASTER)
JM Bueno-de-Mesquita, WH van Harten, VP Retel, LJ van't Veer, ...
The lancet oncology 8 (12), 1079-1087, 2007
Marking axillary lymph nodes with radioactive iodine seeds for axillary staging after neoadjuvant systemic treatment in breast cancer patients: the MARI procedure
M Donker, ME Straver, J Wesseling, CE Loo, M Schot, CA Drukker, ...
Annals of surgery 261 (2), 378-382, 2015
Somatic mutations in the chromatin remodeling gene ARID1A occur in several tumor types
S Jones, M Li, DW Parsons, X Zhang, J Wesseling, P Kristel, MK Schmidt, ...
Human mutation 33 (1), 100-103, 2012
The 70-gene signature as a response predictor for neoadjuvant chemotherapy in breast cancer
ME Straver, AM Glas, J Hannemann, J Wesseling, MJ van de Vijver, ...
Breast cancer research and treatment 119 (3), 551-558, 2010
Magnetic resonance imaging response monitoring of breast cancer during neoadjuvant chemotherapy: relevance of breast cancer subtype
CE Loo, ME Straver, S Rodenhuis, SH Muller, J Wesseling, ...
Journal of Clinical Oncology 29 (6), 660-666, 2011
Feasibility of a prospective, randomised, open-label, international multicentre, phase III, non-inferiority trial to assess the safety of active surveillance for low risk …
LE Elshof, K Tryfonidis, L Slaets, AE van Leeuwen-Stok, VP Skinner, N Dif, ...
European journal of cancer 51 (12), 1497-1510, 2015
Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer
RL Milne, KB Kuchenbaecker, K Michailidou, J Beesley, S Kar, ...
Nature genetics 49 (12), 1767-1778, 2017
A prospective evaluation of a breast cancer prognosis signature in the observational RASTER study
CA Drukker, JM Bueno‐de‐Mesquita, VP Retèl, WH van Harten, ...
International journal of cancer 133 (4), 929-936, 2013
Tissue distribution of the death ligand TRAIL and its receptors
DC Spierings, EG de Vries, E Vellenga, FA van den Heuvel, JJ Koornstra, ...
Journal of Histochemistry & Cytochemistry 52 (6), 821-831, 2004
Triple-negative breast cancer: BRCAness and concordance of clinical features with BRCA1-mutation carriers
EH Lips, L Mulder, A Oonk, LE Van Der Kolk, FBL Hogervorst, ALT Imholz, ...
British journal of cancer 108 (10), 2172-2177, 2013
Receptor conversion in distant breast cancer metastases
LDC Hoefnagel, MJ van de Vijver, HJ Van Slooten, P Wesseling, ...
Breast cancer research 12 (5), 1-9, 2010
The insulin-like growth factor 1 receptor in cancer: old focus, new future
H Hartog, J Wesseling, HM Boezen, WTA van der Graaf
European journal of cancer 43 (13), 1895-1904, 2007
Concordance of clinical and molecular breast cancer subtyping in the context of preoperative chemotherapy response
JJ de Ronde, J Hannemann, H Halfwerk, L Mulder, ME Straver, ...
Breast cancer research and treatment 119 (1), 119-126, 2010
Recommendations for standardized pathological characterization of residual disease for neoadjuvant clinical trials of breast cancer by the BIG-NABCG collaboration
V Bossuyt, E Provenzano, WF Symmans, JC Boughey, C Coles, ...
Annals of oncology 26 (7), 1280-1291, 2015
The system can't perform the operation now. Try again later.
Articles 1–20